Fresh, sourced stories worth posting about for biotech & pharma professionals — updated every few hours, with the receipts attached. Not generated guesses.
Your desk is ready
Free to start · no card required · your pick is waiting on the other side.
Niche's weekly rollup — one email, no spam.
The stories refresh every few hours from live news and primary sources. Each carries the publisher and the date it was published — so you can see exactly how current it is.
Real reporting and primary filings — every story links its sources. Nothing here is a generated guess; the angle is identified and the receipts are attached.
Yes. These are starting points for your own posts. Draft one and Niche writes it in your voice, platform-native, ready to publish.
A broad set of NIH RePORTER awards highlights upstream life-sciences research across Alzheimer’s disease, depression, cervical cancer screening, smoking cessation, vaccine immunology, and pediatric pharmacokinetics. While not company-specific, these grants map the scientific substrate feeding future drug discovery and clinical development pipelines.
Draft a post from this →Recent company updates point to a cluster of positive late-stage or near-pivotal clinical developments, led by Definium Therapeutics' third positive Phase 3 anxiety readout ahead of an NDA submission and Structure Therapeutics' advancing oral obesity program with Phase 3 data readouts approaching. Together these signals reflect the current market focus on de-risked assets moving toward registration and commercialization.
Draft a post from this →A set of oncology-oriented and clinical-development updates spans Inhibrx's positive randomized Phase 2 head and neck cancer data, plus 8-K filings from Pyxis Oncology, Kura Oncology, and related development-stage names. The thread is continued trial execution and corporate disclosure across small-cap oncology developers.
Draft a post from this →Novartis' stock slide following Avidity's failed crucial Phase 3 readout underscores the risk embedded in large-biotech acquisition strategies that depend on late-stage clinical success. This single high-salience signal stands out as essential context for current life-sciences investing and partnering sentiment.
Draft a post from this →